Tempest Therapeutics (TPST) News Today $0.82 +0.03 (+4.30%) Closing price 03/5/2025 04:00 PM EasternExtended Trading$0.80 -0.02 (-1.98%) As of 07:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Tempest Therapeutics granted FTD from FDA for amezalpatFebruary 11, 2025 | markets.businessinsider.comTempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular CarcinomaFebruary 10, 2025 | globenewswire.comTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 | globenewswire.comFDA grants ODD to Tempest’s hepatocellular carcinoma treatmentJanuary 7, 2025 | finance.yahoo.comTempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)January 6, 2025 | globenewswire.comTempest Therapeutics Inc TPSTDecember 15, 2024 | morningstar.comTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 6, 2024 | globenewswire.comFavourable Signals For Tempest Therapeutics: Numerous Insiders Acquired StockNovember 28, 2024 | finance.yahoo.comTempest to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 25, 2024 | globenewswire.comTempest Therapeutics Reports Q3 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comTempest Therapeutics price target lowered to $5 from $8 at Piper SandlerNovember 13, 2024 | markets.businessinsider.comTempest Therapeutics: Promising Advancements and Strategic Partnerships Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comTempest Therapeutics: Tempest Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | finanznachrichten.deTempest receives FDA study may proceed for Phase 3 trial of amezalpatNovember 13, 2024 | markets.businessinsider.comTempest Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | finance.yahoo.comTempest Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | globenewswire.comTempest Therpeutics options imply 22.5% move in share price post-earningsNovember 9, 2024 | markets.businessinsider.comTraders Digest Consumer Inflation Measure as US Equity Futures Drop Pre-BellOctober 12, 2024 | msn.comScotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)October 11, 2024 | markets.businessinsider.comTempest Agrees To Extend Limited Duration Stockholder Rights PlanOctober 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tempest Therapeutics Amid Positive Developments and Strategic Roche CollaborationOctober 10, 2024 | markets.businessinsider.comWhy Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?October 10, 2024 | finance.yahoo.comPerimeter Solutions (NYSE:PRM) Stock Quotes, Forecast and News SummaryOctober 10, 2024 | benzinga.comTempest Inks Deal With Roche To Support Advancement Of Amezalpat Combination TherapyOctober 10, 2024 | markets.businessinsider.comTempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal TrialOctober 10, 2024 | globenewswire.comTempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 20, 2024 | globenewswire.comTempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory AffairsSeptember 18, 2024 | finance.yahoo.comTempest Flounders on News of Test ResultsSeptember 13, 2024 | msn.comTempest to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | globenewswire.comTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 23, 2024 | globenewswire.comTempest set to storm the HCC landscape with promising Phase II amezalpat dataAugust 21, 2024 | finance.yahoo.comTempest Announces the Appointment of Troy M. Wagner as Vice President of Quality AssuranceAugust 21, 2024 | finance.yahoo.comScotiabank maintains a target on Tempest Therapeutics stockAugust 18, 2024 | uk.investing.comBuy Rating Affirmed for Tempest Therapeutics Amidst Promising Phase 3 Outlook and Funding UncertaintiesAugust 15, 2024 | markets.businessinsider.comTempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular CarcinomaAugust 15, 2024 | globenewswire.comTempest Therapeutics, Inc. (NASDAQ:TPST) Major Shareholder Versant Venture Capital Vi, L. Sells 387,999 SharesAugust 13, 2024 | insidertrades.comBuy Rating Affirmed for Tempest Therapeutics Amid Strong Clinical Results and Solid FinancialsAugust 9, 2024 | markets.businessinsider.comTPST Stock Earnings: Tempest Therapeutics Misses EPS for Q2 2024August 9, 2024 | investorplace.comTempest Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 8, 2024 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), CVS Health (CVS) and Tempest Therapeutics (TPST)July 27, 2024 | markets.businessinsider.comTempest Therapeutics, Inc. (NASDAQ:TPST) CEO Purchases $73,850.00 in StockJuly 9, 2024 | insidertrades.comTempest Therapeutics, Inc. (NASDAQ:TPST) Insider Justin Trojanowski Purchases 7,500 SharesJuly 3, 2024 | insidertrades.comWhat's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?June 20, 2024 | benzinga.comWhy Is Tempest Therapeutics (TPST) Stock Up 45% Today?June 20, 2024 | investorplace.comTempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular CarcinomaJune 18, 2024 | globenewswire.comTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 7, 2024 | globenewswire.comGlancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)May 31, 2024 | businesswire.comTempest to Participate in Upcoming Investor ConferencesMay 21, 2024 | finance.yahoo.comTempest Therapeutics, Inc. (NASDAQ:TPST) Sees Significant Increase in Short InterestTempest Therapeutics, Inc. (NASDAQ:TPST - Get Free Report) was the target of a large growth in short interest in April. As of April 30th, there was short interest totalling 1,580,000 shares, a growth of 39.8% from the April 15th total of 1,130,000 shares. Based on an average daily trading volume, of 901,800 shares, the short-interest ratio is presently 1.8 days. Currently, 9.4% of the company's stock are sold short.May 12, 2024 | marketbeat.comBuy Rating Affirmed for Tempest Therapeutics Amidst Promising Clinical AdvancementsMay 10, 2024 | markets.businessinsider.com Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Email Address TPST Media Mentions By Week TPST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TPST News Sentiment▼1.890.67▲Average Medical News Sentiment TPST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TPST Articles This Week▼01▲TPST Articles Average Week Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ZNTL News EPRX News OGI News ADAP News SLN News ACTU News MCRB News TSVT News GNLX News CKPT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TPST) was last updated on 3/6/2025 by MarketBeat.com Staff From Our Partners77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempest Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TPST Stock Alerts